🔥🐔 BizChicken 🐔🔥

Companies Similar to REGENXBIO Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. logo
Market Cap: Lowest
Employees: Lowest

BRTX-100

Bio Restorative Therapies, Inc., a life sciences company, focuses on developing regenerative medicine products and therapies primarily involving adult stem cells to treat disc/spine disease and metabolic disorders.

Tags: biotechnology, cell therapy, disc/spine disease, metabolic disorders, regenerative medicine, stem cells

Symbol: BRTX

Recent Price: $1.44

Industry: Biotechnology

CEO: Mr. Lance Alstodt

Sector: Healthcare

Employees: 11

Address: 40 Marcus Drive, Melville, NY 11747

Phone: 631 760 8100

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Novavax, Inc.

Novavax, Inc. logo
Market Cap: High
Employees: Medium

NVX-Co V2373

Novavax, Inc. is a biotechnology company focused on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Their vaccine candidates include NVX-Co V2373, Nano Flu, and Res Vax. The company operates collaboratively with Takeda Pharmaceutical Company Limited on COVID-19 vaccine development.

Tags: COVID-19, biotechnology, clinical trials, infectious diseases, vaccines

Symbol: NVAX

Recent Price: $7.93

Industry: Biotechnology

CEO: Mr. John Charles Jacobs M.B.A.

Sector: Healthcare

Employees: 1543

Address: 21 Firstfield Road, Gaithersburg, MD 20878

Phone: 240 268 2000

Last updated: 2024-12-31

Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock logo
Market Cap: High
Employees: Low

navacaprant (NMRA-140)

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Key programs include navacaprant for major depressive disorder, and several promising treatments in various stages of clinical and preclinical trials targeting conditions such as Alzheimer's, schizophrenia, and Parkinson's disease.

Tags: biopharmaceutical, brain diseases, clinical trials, neurodegenerative diseases, neuropsychiatric disorders

Symbol: NMRA

Recent Price: $11.06

Industry: Biotechnology

CEO: Mr. Henry O. Gosebruch

Sector: Healthcare

Employees: 108

Address: 490 Arsenal Way, Watertown, null 02472

Phone: 857 760 0900

Last updated: 2024-12-31

Revelation Biosciences, Inc.

Revelation Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

REVTx-99b

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immune system therapeutics and diagnostics, including products for chronic nasal congestion, allergic rhinitis, chronic organ disease, and viral infections.

Tags: allergic rhinitis, biopharmaceutical, clinical trial, diagnostics, immune system therapeutics, kidney disease, nasal congestion, viral infections

Symbol: REVB

Recent Price: $0.39

Industry: Biotechnology

CEO: Mr. James M. Rolke

Sector: Healthcare

Employees: 9

Address: 4660 La Jolla Village Drive, San Diego, CA 92122

Phone: 650-800-3717

Last updated: 2024-12-31

Agenus Inc.

Agenus Inc. logo
Market Cap: Low
Employees: Medium

Retrocyte Display

Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.

Tags: antibody expression, cancer treatment, clinical trials, immuno-oncology, vaccine development

Symbol: AGEN

Recent Price: $2.69

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 389

Address: 3 Forbes Road, Lexington, MA 02421-7305

Phone: 781 674 4400

Last updated: 2024-12-31

Anavex Life Sciences Corp.

Anavex Life Sciences Corp. logo
Market Cap: Medium
Employees: Lowest

ANAVEX 2-73

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company developing drug candidates for CNS diseases, including Alzheimer's, Rett syndrome, and Parkinson's.

Tags: Alzheimer's, CNS diseases, Parkinson's, Rett syndrome, biopharmaceutical, clinical trials, neurodegenerative diseases

Symbol: AVXL

Recent Price: $11.04

Industry: Biotechnology

CEO: Dr. Christopher U. Missling M.B.A., M.S., Ph.D.

Sector: Healthcare

Employees: 40

Address: 51 West 52nd Street, New York, NY 10019

Phone: 844 689 3939

Last updated: 2024-12-31

NexImmune, Inc.

NexImmune, Inc. logo
Market Cap: Lowest
Employees: Lowest

Artificial Immune Modulation

Nex Immune, Inc., a clinical-stage biotechnology company, develops therapies for cancer and immune-mediated diseases using its Artificial Immune Modulation platform. The company is advancing cell therapy candidates including NEXI-001, NEXI-002, and NEXI-003.

Tags: T cell immunotherapies, biotechnology, cancer, cell therapy, immune-mediated diseases, nanoparticle technology

Symbol: NEXI

Recent Price: $0.15

Industry: Biotechnology

CEO: Mr. John Trainer M.B.A.

Sector: Healthcare

Employees: 6

Address: 9119 Gaither Road, Gaithersburg, MD 20877

Phone: 301 825 9810

Leadership

  • Kristi Jones, Chief Executive Officer
  • Mathias Oelke, Ph.D., Chief Scientific Officer
  • Daniel Bednarik Ph.D., Senior Vice President, Molecular Engineering & Protein Design
  • Jack Ragheb, Senior Vice President, Translational Science
  • Tonya Catterton, Vice President, Quality & Compliance
  • Tim Stover, Vice President, Corporate Controller
  • Karen Haslbeck, Head, Human Resources
  • Matt Schiller, Head, Business Development

Last updated: 2024-12-31

Neurogene Inc.

Neurogene Inc. logo
Market Cap: Medium
Employees: Low

NGN-401, NGN-101

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases, focusing on gene therapy products like NGN-401 for Rett syndrome and NGN-101 for neuronal ceroid lipofuscinosis subtype 5 batten disease.

Tags: Rett syndrome, biotechnology, gene therapy, genetic medicines, life sciences, neurological diseases, neuronal ceroid lipofuscinosis

Symbol: NGNE

Recent Price: $22.28

Industry: Biotechnology

CEO: Dr. Rachel L. McMinn Ph.D.

Sector: Healthcare

Employees: 91

Address: 535 W 24th Street, New York, NY 10011

Phone: (877) 237-5020

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

Gene Therapies

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.

Tags: Biotechnology, Clinical Stage, Gene Therapy, Healthcare, Rare Diseases

Symbol: RCKT

Recent Price: $12.03

Industry: Biotechnology

CEO: Dr. Gaurav D. Shah M.D.

Sector: Healthcare

Employees: 268

Address: 9 Cedarbrook Drive, Cranbury, NJ 08512

Phone: 609 659 8001

Last updated: 2024-12-31

Regulus Therapeutics Inc.

Regulus Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

RG-012 and RGLS8429

Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.

Tags: biopharmaceutical, clinical stage, drug development, kidney disease, micro RNAs

Symbol: RGLS

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Joseph P. Hagan M.B.A.

Sector: Healthcare

Employees: 30

Address: 4224 Campus Point Court, San Diego, CA 92121

Phone: 858 202 6300

Last updated: 2024-12-31

REGENXBIO Inc.

REGENXBIO Inc. logo
Market Cap: Medium
Employees: Medium

NAV Technology Platform

REGENXBIO Inc. is a biotechnology company focusing on gene therapy product candidates to treat genetic defects and enable therapeutic protein production, using its proprietary NAV Technology Platform. Its lead candidate, RGX-314, is in Phase III trials for wet age-related macular degeneration.

Tags: Biotechnology, Clinical Trials, Gene Therapy, NAV Technology Platform, Therapeutic Proteins

Symbol: RGNX

Recent Price: $7.23

Industry: Biotechnology

CEO: Mr. Curran M. Simpson M.S.

Sector: Healthcare

Employees: 344

Address: 9804 Medical Center Drive, Rockville, MD 20850

Phone: 240 552 8181

Last updated: 2024-12-31

Rallybio Corporation

Rallybio Corporation logo
Market Cap: Lowest
Employees: Lowest

RLYB212

Rallybio Corporation is a clinical-stage biotechnology company focused on discovering, developing, manufacturing, and delivering therapies for severe and rare diseases, with a lead product candidate RLYB212 in clinical trials.

Tags: biotechnology, clinical trials, monoclonal antibodies, rare diseases, therapeutics

Symbol: RLYB

Recent Price: $0.93

Industry: Biotechnology

CEO: Dr. Stephen Uden M.B, M.D.

Sector: Healthcare

Employees: 25

Address: 234 Church Street, New Haven, CT 06510

Phone: 203 859 3820

Last updated: 2024-12-31

RenovoRx, Inc.

RenovoRx, Inc. logo
Market Cap: Lowest
Employees: Lowest

Renovo Gem

Renovo Rx, Inc. is a clinical-stage biopharmaceutical company focusing on developing therapies for the treatment of solid tumors, with its lead product candidate, Renovo Gem, in Phase III clinical trials for locally advanced pancreatic cancer.

Tags: Renovo Gem, biopharmaceutical, clinical trials, pancreatic cancer, solid tumors

Symbol: RNXT

Recent Price: $1.39

Industry: Biotechnology

CEO: Mr. Shaun R. Bagai

Sector: Healthcare

Employees: 8

Address: 4546 El Camino Real, Los Altos, CA 94022

Phone: 650 284 4433

Leadership

  • Shaun R. Bagai, Director and Chief Executive Officer
  • Ramtin Agah, MD, Chairman, Chief Medical Officer, and Founder
  • Leesa Gentry, Chief Clinical Officer
  • Ronald B. Kocak, CPA, VP Controller and Principal Accounting Officer
  • Ryan Witt, Senior Vice President, Head of Corporate Strategy and Partnerships
  • Imtiaz Qureshi, MD, Director of Imaging
  • Angela Macfarlane, CEO of Perceive Biotherapeutics, Inc.
  • Laurence J. Marton, MD, Director
  • Una S. Ryan, PhD, OBE, Director
  • Robert J. Spiegel, Director

Last updated: 2024-12-31

Vaxxinity, Inc.

Vaxxinity, Inc. logo
Market Cap: Lowest
Employees: Lowest

UB-311, UB-312, UB-313, UB-612

Vaxxinity, Inc. is a biotechnology company focused on developing product candidates for neurology and coronavirus-related treatments, including Alzheimer's, Parkinson's disease, migraines, and SARS-CoV-2.

Tags: Alzheimer's disease, Parkinson's disease, SARS-CoV-2, biotechnology, migraines, neurology

Symbol: VAXX

Recent Price: $0.00

Industry: Biotechnology

CEO: Ms. Mei Mei Hu J.D.

Sector: Healthcare

Employees: 57

Address: 1717 Main Street, Dallas, TX 75201

Phone: 254 244 5739

Last updated: 2024-11-08

Nuvation Bio Inc.

Nuvation Bio Inc. logo
Market Cap: Medium
Employees: Low

NUV-422

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focusing on the development of therapeutic candidates for oncology, such as NUV-422, a small molecule inhibitor targeting cyclin-dependent kinases, among other innovative treatments.

Tags: NUV-422, biopharmaceutical, oncology, therapeutic development

Symbol: NUVB

Recent Price: $2.62

Industry: Biotechnology

CEO: Dr. David T. Hung M.D.

Sector: Healthcare

Employees: 51

Address: 1500 Broadway, New York, NY 10036

Phone: 332 208 6102

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31